# Effect of SGLT2 Inhibition on OCT-A Parameters in Diabetic CKD

> **NCT04215445** · PHASE4 · UNKNOWN · sponsor: **National University of Malaysia** · enrollment: 90 (estimated)

## Conditions studied

- Diabetic Retinopathy
- Chronic Kidney Diseases
- Diabetes Mellitus

## Interventions

- **DRUG:** Empagliflozin 25 MG
- **DEVICE:** OCT-A

## Key facts

- **NCT ID:** NCT04215445
- **Lead sponsor:** National University of Malaysia
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-01
- **Primary completion:** 2020-05
- **Final completion:** 2020-08
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2020-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04215445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04215445, "Effect of SGLT2 Inhibition on OCT-A Parameters in Diabetic CKD". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04215445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*